An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Original Article
[키워드] accelerate
acute respiratory syndrome
Adults
adverse event
age
antibody
Antibody Response
candidate vaccine
chills
conducted
convalescent serum
coronavirus
distribution
dose
dose-escalation
effort
ENCODE
enzyme-linked immunosorbent
evaluated
fatigue
first vaccination
geometric mean titer
GMT
headache
healthy
highest dose
immune response
Infectious disease
injection
International
mRNA
mRNA-1273
mRNA-1273 vaccine
myalgia
occurred
Open-label
Pain
participant
Participants
prefusion
report
reported
Result
SARS-CoV-2
SARS-CoV-2 spike protein
second vaccination
severe adverse events
specimens
Spread
Support
systemic
Trial
Vaccinations
Vaccine
[DOI] 10.1056/NEJMoa2022483 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1056/NEJMoa2022483 PMC 바로가기 [Article Type] Original Article